EurekAlert! -
10 Dec 2017 07:00
(Dana-Farber Cancer Institute) Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.
Share this Article